• DE
  • EN
  • Stuart Parkin – Encouraging young people to follow seemingly crazy ideas

    "Let us encourage young people to follow seemingly crazy ideas"

    Why Stuart Parkin, Director at the Max Planck Institute of Microstructure Physics, gave up his top job in California, how he is giving data processing a leg up and what future he sees for Germany.  

    Professor Parkin, a few years ago you were still at IBM in Silicon Valley, now you work in Halle an der Saale. Was that a good swap?
    I think so, even though the two stations are very different. However, they are similar in one respect, which is very important to me, and that is scientific freedom. I had that as research director at IBM and here at the Max Planck Institute for Microstructure Physics in Halle I can also determine my own course.

    And yet it's a big leap you've made: from industrial research to a publicly funded institute, from California to Saxony-Anhalt. What made you do it?
    My love for my wife Claudia Felser. We met at Stanford and decided to move to Germany together a few years ago. She is a chemistry professor and director at the Max Planck Institute for Chemical Physics of Solids in Dresden. We are not far from our home to our institutes. Not only do we share a fascination for new materials, we also work together on projects.

    © Max Planck Institut fuer Mikrostrukturphysik

    The Max Planck Institute for Microstructure Physics was founded in 1992 as the first institute of the Max Planck Society in East Germany. The research focus is on novel materials with useful functionalities. Today, the institute offers space for around 150 employees.

    What exactly is your research about?
    To put it in a nutshell: I create completely new materials for information processing. They are needed because we are at the end of the silicon age and urgently need basic materials for a faster, more efficient data world. Our materials consist of wafer-thin magnetic layers.  They make it possible to use the magnetic moment of the electron to store and process digital data, and not just its electrical charge, as used to be the case in semiconductor electronics. Spintronics is the corresponding technical term. I have dedicated most of my professional life to it and during this time I was able to make a significant contribution to the fact that magnetic drives are standard today. But that is only part of the story.

    How does it continue?
    One important spintronics application is the spin valves I invented. These are thin-film read heads that can detect very small magnetic domains on hard drives and significantly increase their storage capacity. More than ten years ago, the so-called Racetrack memory was developed under my leadership. This technology, based on magnetoelectronics, processes digital information a million times faster than conventional hard disks. Currently, together with my wife, I am researching skyrmions and antiskyrmions, i.e. nanometre-sized magnetic objects that could pave the way for ultra-fast and at the same time power-saving data processing in the future. Our results have been published in high-ranking journals, most recently in Nature.

    When it comes to efficient information processing, the human brain is unrivalled. Do you draw inspiration from it?
    Of course I do. I already started my first studies at IBM and we are also working in this extremely exciting field in Halle. We want to understand how the brain manages to trigger material reactions by means of tiny ionic currents. That is electrochemistry at its finest. Our goal is to mimic the incredibly economical and precise way the brain works. This cannot be achieved in the short term, you need staying power. 

    What can be achieved in the next few years?
    For me, it's about accelerating the invention of new materials. That's why I completely rebuilt the institute in Halle and received excellent support from the state of Saxony-Anhalt, the Max Planck Society and the Alexander von Humboldt Foundation. Today we work here in a large team of physicists, chemists and biologists – to name just a few disciplines. We have state-of-the-art imaging technology at our disposal and a new clean room in which we can produce the finest nanostructures.  Most of it we built ourselves, you can't buy something like that on the market.

    © burckhardt+partner

    New research building for the chip technology of tomorrow (virtual view): With an investment of 50 million euros, the Max Planck Institute for Microstructure Physics in Halle is being expanded with modern laboratories and offices. The new building with a floor space of 5,500 square metres is scheduled for completion by the end of 2024. The institute will then be able to accommodate up to 300 employees.

    Your research should be of great interest to industry?
    That's right. There are collaborations with the Korean IT company Samsung, for example. Other companies are also keeping a close eye on what we are doing. Among them is the American chip manufacturer Intel, which recently announced billions in investments in Europe. 

    How do you rate the general conditions for your research in Germany?
    We have really good conditions. A big plus is that Germany invests a lot in basic research, much more than other countries in Europe. There are excellent specialists in the country and ambitious young people with good ideas.

    Where do you see Germany in international comparison?
    There is still some catching up to do. Let's take the example of the USA: there, digitalisation has really arrived in the middle of society, but I don't see it that way in Germany yet. The powerful and rich companies in Silicon Valley can pay professionals high salaries, and we often can't keep up. Moreover, many patent rights are in the USA – that also makes competition more difficult. The pandemic has shown how big the differences are between countries. All of a sudden, video conferencing was en vogue and US providers like Zoom or MS Teams were at the forefront. Why, I ask myself, is a German company like SAP not playing along? The prerequisites are certainly there.

    How can Germany make up ground?
    The best way is to invest in young people. We should encourage them to follow even seemingly crazy ideas and take risks. At universities, people should be able to learn how innovation works and how to compete successfully. Some Asian countries designate certain zones where company founders do not have to pay taxes for ten years. This could also be a model for us, especially in eastern Germany, where there are still many vacant areas.

    The federal elections are just behind us, the coalition negotiations are underway. What do you expect from the next federal government in your field?
    A strong push for digitalisation. As the leading economy, Germany should lead the way in this area and help Europe speak with one voice. That would be important in order to survive in international competition and to enforce important values such as data security.

    You are involved in numerous professional societies. How important is your work in the GDNÄ for you?
    I am a European and would like to contribute to making our continent more competitive. The GDNÄ can play an important role in this, for example by supporting young people. But also by inviting controversial, cultivated discussions about current scientific topics. I know this from Great Britain and would like to see more public debate of this kind in this country as well. It could be a good remedy for the increasing scepticism about science in society.

    Saarbrücken 2018 © Robertus Koppies

    © Sven Doering

    © Sven Doering

    Stuart S. P. Parkin

    About the person
    Stuart S. P. Parkin was born in Watford, England, in 1955. After completing his doctorate in solid-state physics at the University of Cambridge, he joined IBM as a postdoctoral researcher, where he was made a Fellow in 1999, the company's highest technical award. Between 2004 and 2006, he conducted research at the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University with a Humboldt Research Award. Professor Parkin headed the IBM Almaden Research Center in San Jose, and was director of the Spintronic Science and Applications Center (SpinAps), founded in 2004. He was also a professor at Stanford University. He is a member of numerous international academies such as the Royal Society and the American Academy of Arts and Sciences and has received numerous awards, most recently the King Faisal Prize 2021 worth 200,000 dollars. The physicist with three citizenships in the UK, USA and Germany has published around 400 scientific papers and holds more than 90 patents. Since 2014, he has been director at the MPI for Microstructure Physics Halle and Alexander von Humboldt Professor at the Institute of Physics at Martin Luther University Halle-Wittenberg. Shortly afterwards, Stuart Parkin joined the GDNÄ and was elected subject representative for engineering sciences.

    Further Information:

    Jürgen Floege The pandemic has driven us deep into the red

    "The pandemic has driven us deep into the red“

    Now it's up to the politicians, says Professor Jürgen Floege. He heads the University Clinic for Renal and Hypertension Diseases in Aachen, is committed to more research and likes to think outside the box – also in the GDNÄ.

    Professor Floege, with what thoughts and feelings do you as clinic director look forward to the second pandemic winter?
    I am relatively relaxed. I don't expect the kind of strain we had at the beginning of the pandemic this winter. In the spring of 2020, there were many seriously ill patients on the wards, which also had to do with the geographical proximity to the then Corona hotspot Heinsberg. We are currently looking after about a dozen Covid 19 patients in our clinic. One hundred percent of them are unvaccinated. Some of them are young and have no previous illnesses, yet they now have to be artificially ventilated. This shows quite clearly that no immune system, no matter how strong, can help against this disease; the best protection is offered by vaccination.

    Do the employees in your clinic also see it that way?
    Yes, most of them have been vaccinated twice. In the meantime, many of them – including myself –have had a third vaccination. We don't have any compulsory measures, but we appeal for common sense and consideration. So far, we have done well with this. We are currently concerned about a completely different issue.

    Is it also related to the pandemic?
    Directly. The pandemic has burdened us with high additional expenses and driven us deep into the red. Even before the pandemic, three quarters of the German university hospitals were running deficits, and now almost all of them are like us. Each of these hospitals treats patients that no other hospital can or wants to treat; in addition, we are responsible for training young doctors on a large scale. This costs time and money and is not sufficiently rewarded by the current remuneration system. Therefore, we urgently need supplements, which politicians have so far refused to grant. At my hospital, but also in many other hospitals, this has led to an investment backlog of the highest order. Important projects now have to wait.

    © Peter Winandy

    The University Hospital Aachen was founded in 1985 and today employs around 8,500 staff in 35 specialist clinics, 30 institutes and six interdisciplinary units. Every year, more than 50,000 patients are treated there as inpatients and a good 200,000 as outpatients. The hospital is located in the west of Aachen in the immediate vicinity of the municipality of Vaals in the Netherlands.

    Your speciality is the kidney - an organ that medical laypeople do not necessarily associate with the coronavirus.
    Yet the kidneys are one of the most frequently affected organs after the nasal mucosa and lungs. One third of all people who are severely affected by Covid-19 suffer from kidney failure. And it is not at all rare for an infection to lead to late damage in the kidneys that does not disappear.

    How common is kidney damage in this country?
    Very common. In about four million people, the kidney function is below 30 percent of its possible capacity. And in half a million people, kidney function has dropped to 15 percent or less. If the function drops to five to seven percent, those affected are dependent on dialysis as kidney replacement therapy, unless a new kidney is available for transplantation.

    It is estimated that kidney disease will be the fifth leading cause of death worldwide by 2040. Yet in your field, nephrology, there are currently the fewest clinical trials for new therapies. Why is that?
    It has to do with the complexity of kidney diseases. They are difficult to control and difficult to research. Very few patients only have kidney problems; most of them also suffer from diseases of the cardiovascular system, the lungs or the gastrointestinal tract, to name just a few diagnoses. People with pronounced kidney damage are often kept away from drug studies because these studies depend on a functioning organ – after all, the vast majority of active pharmaceutical ingredients are excreted via the kidneys. In addition, the treatment of kidney patients is highly individualised, there are hardly any standard prescriptions. And medicines that have the intended effect in healthy kidney patients can in some cases have a completely different effect in patients with severe kidney disease.

    © J. Floege

    Visiting dialysis patients is part of the daily work of Jürgen Floege's team.

    Nevertheless, there is a lot of research going on in your clinic. On which topics?
    Apart from kidney diseases, it is about rheumatological-immunological diseases. We initiate and participate in clinical studies, but also do basic research. Just recently, the Collaborative Research Centre "Mechanisms of Cardiovascular Complications in Chronic Renal Insufficiency", which we run together with the outstanding heart specialists at our university, was rated very highly and recommended for a second funding period. We are also involved in Covid-19 research: some colleagues are currently in the process of creating an artificial kidney in the test tube in order to test new therapeutic approaches on it. With my own research group, I want to find out whether high-dose administration of the coagulation vitamin K can help dialysis patients. There are indications that the K2 variant in particular protects the blood vessels that are under great strain in chronic kidney disease. K2 is only found in very few foods, for example in the Japanese soy product natto. For our study, we use synthetically produced vitamin.

    What can we do ourselvesf for healthy kidneys?
    It is important to have a normal weight, blood pressure values below 130/80 millimetres of mercury and little salt. The optimal salt intake is up to five grams a day, which corresponds to just one teaspoon – much more is unhealthy. In addition, diabetes is associated with a considerable risk of kidney disease: For this reason, too, the disease should be avoided if possible or the blood sugar should be well adjusted if the disease is present.

    Allow me to ask you a personal question: How did you get involved in kidney research yourself?
    It was clear to me early on that I wanted to do medicine. The decision also had to do with the early death of my father. In the 1970s there wasn't much we could do about his heart attacks, fortunately there was a lot of progress. I spent my training years in Hanover, New York and Seattle and became more and more interested in renal medicine.

    © Peter Winandy

    The University Hospital of RWTH Aachen University (pictured front left) is one of the largest hospital buildings in Europe. North of it is the Melaten Campus with technology-oriented research facilities of RWTH and companies.

    You have now been working in Aachen for more than twenty years. How does it feel to work as a medical doctor at a technical university?
    Today I am doing very well here. It was different when I took up my post at the end of the 1990s. At that time, medicine was more of an appendage of the technical subjects here. The German Science Council took a look at that in 2000 and recommended that the state of North Rhine-Westphalia close the medical faculty. What followed was a huge jolt. Everyone made an effort, a lot of fresh research money was raised, good scientists were appointed and to this day great young people are vitalising the operation – we have become a highly esteemed and valued faculty within RWTH Aachen University.

    How did you become a GDNÄ member?
    I joined only recently, at the suggestion of the Würzburg cardiologist, Professor Georg Ertl. He also won me over to take on the task of group chairman for medicine.

    As a clinician and researcher, you do not suffer from a lack of work. What made you decide to get additionally involved in the GDNÄ?
    I like to look beyond the horizon of my discipline and am very interested in other areas of the natural sciences. The GDNÄ meets this need with its diversity of subjects. What also fascinates me is the great tradition – that is already unique.

    Do you have any ideas for the future of the GDNÄ?
    I think we need a "Young GDNÄ" parallel to the established Society of German Natural Scientists and Physicians. Role models could be the Young Internists within the German Society for Internal Medicine or the Young Academy of the Berlin-Brandenburg Academy of Sciences and the Leopoldina. It is important that the young people organise themselves and can be productive independently of their elders.

    Saarbrücken 2018 © Robertus Koppies

    © J. Floege

    Prof. Dr. Jürgen Floege

    About the person
    Since 1999, Professor Dr. med. Jürgen Floege has been head of the Medical Clinic II of the University Hospital RWTH Aachen (Clinic for Kidney and High Pressure Diseases, Rheumatological and Immunological Diseases). He studied at the Hannover Medical School and at the Albert Einstein College of Medicine in New York. In Hanover he completed his specialist training, habilitated and took up a position as senior physician in 1995. In the 1990s, he also worked for three years as a visiting scientist at the University of Washington in Seattle. His scientific focus, on which he has published more than 600 original articles, reviews, editorials and book chapters, includes kidney diseases and their central importance for internal medicine, for example in the development of cardiovascular diseases. Professor Floege is the editor of the international best-selling textbook "Comprehensive Clinical Nephrology" and co-editor of the leading nephrology journal "Kidney International". He has received numerous honours for his research, including the highest award of the German Society for Nephrology (DGfN), the Franz Volhard Medal, in 2020. In addition to his clinical activities, Floege is involved in renowned societies, committees and organisations. He is a founding member and past-president of the German Society for Nephrology (DGfN), past-president of the German Society for Internal Medicine (DGIM) and on the steering committee of KDIGO – an organisation that draws up globally valid guidelines for nephrology. Jürgen Floege has been a member of the GDNÄ since 2019; he has taken on the role of Group Chair of Medicine.

    Further Links:

    Lasker Award for GDNÄ member

    Lasker Award for GDNÄ member

    Professor Dieter Oesterhelt receives high honor for his merits in optogenetics

    A pioneer in optogenetics, longtime GDNÄ member and director emeritus at the Max Planck Institute of Biochemistry, Professor Dieter Oesterhelt, has been awarded the most prestigious biomedical research prize in the United States.

    Oesterhelt will receive the Albert Lasker Award 2021, which is endowed with $250,000, together with his academic student Professor Peter Hegemann of Berlin's Humboldt University and Professor Karl Deisseroth, who conducts research at Stanford University. The three scientists are being honored for the discovery of light-sensitive proteins in the membrane of unicellular organisms and their use in the further development of optogenetics. With their research, the laureates paved the way for numerous medical applications, including new therapeutic approaches to blindness. Many recipients of the Lasker Prize went on to win the Nobel Prize.

    © Krella, Archiv der Max-Planck-Gesellschaft Berlin

    Dieter Oesterhelt (left) with his doctoral supervisor and Nobel laureate Feodor Lynen, 1967

    Dietrich von Engelhardt – In free speech and friendly solidarity

    “In free speech and friendly solidarity”

    Born in the spirit of awakening, the GDNÄ has always been a forum for great debate and thoughtful analysis. How it has managed this over almost two centuries is described here by the historian of science Dietrich von Engelhardt.

    Professor von Engelhardt, next year the GDNÄ will be 200 years old. Not all science organisations last that long. How do you explain the robustness of the GDNÄ?
    First and foremost with its uniqueness - also in comparison to other scientific societies. Since its foundation in 1822, its core concern has been the interdisciplinary exchange between natural scientists and medical doctors as well as the connection to philosophy and society. In the humanities, this interest in other disciplines is not as pronounced; there is no comparable overarching humanities society. What also stabilised the GDNÄ were the great scientific debates that took place at its meetings and that radiated far into society and culture.

    Which debates are you thinking of?
    For example, the debates on natural science and natural philosophy, on the freedom of research, Darwin's theory of evolution, mechanism and vitalism, and on popularisation and school education. I am thinking, for example, of Emil du Bois-Reymond's speech at the 45th Assembly in Leipzig in 1872 on "The Limits of Natural Knowledge", which dealt with the relationships between force and substance, body and soul, which, in his view, were fundamentally not discernible by natural science. The speech provoked both agreement and opposition ­– just like Ernst Haeckel's advocacy of Darwin and Darwinism. Rudolf Virchow's plea for the freedom of science and for the renunciation of the dissemination of the unproven in school lessons and in public also triggered a variety of reactions.

    The GDNÄ as a forum for great debates: can it still do that today?
    Today there are many other platforms for the competition of ideas, the GDNÄ has got strong competition. Its heyday was certainly in the 19th and early 20th centuries. But I also see great opportunities for the GDNÄ in our time, be it in the field of education or in the dialogue between disciplines and in its relationship to society and culture. The response of many meetings has shown this impressively and repeatedly. In this perspective, an important and high-profile topic is also “Image in science”, which will be the focus of the 2022 Assembly in Leipzig.

    © Deutsches Museum, München, Archiv, CD79207

    The Mathematics and Astronomy Section at the 1890 GDNÄ meeting.

    Let us go back to the beginnings. The first meeting of the GDNÄ took place in Leipzig, in the autumn of 1822. What were the founders concerned with?
    The driving force was the natural scientist and natural philosopher Lorenz Oken. He had gathered a group of like-minded people around him, including the romantic natural philosopher, painter and physician Carl Gustav Carus and the chemist and mythologist Johann Salomo Christoph Schweigger. Once a year and always in a different city, hence the epithet Wandergesellschaft, they wanted to inform each other about the state of their own research – in free lecture and friendly solidarity, but also in open discussion. The founders were concerned with lively exchange, also as a counter-design to the rituals of the universities and academies of science that had existed for a long time at that time.

    Did they succeed in this from the beginning?
    As far as can be deduced from the sources, yes. Oken's call for the Assembly of German Natural Scientists was answered by 13 natural scientists and physicians as members at the first meeting in 1822; a total of 60 people took part in the lectures and discussions. Later it became much more, occasionally 5000 to 7000 visitors came. In the present, the numbers of members and visitors have declined again – younger scientists are setting other priorities for their careers and research. In the early years, the lectures, entirely in the spirit of the romantic philosophy of nature, were about the unity of nature, the connection between nature and spirit, man's responsibility for nature and also about social commitment. After lively and sometimes controversial discussions, the days came to an end in convivial company with witty table speeches and joint singing.

    Could it be sustained like that?
    Not quite. In 1828, there was a profound structural change and indeed the first crisis. In his speech at the Berlin Assembly, Alexander von Humboldt had strongly advocated the formation of sections in addition to the general sessions, in order to be able to respond appropriately to scientific progress in the individual disciplines and in divergent debate. This initiative was to prove immensely important for the continued existence of the Society, but was initially met with resistance. Some feared a drifting apart of the disciplines, a development that the founding of the GDNÄ had been intended to counteract. Lorenz Oken was also not at all enthusiastic about the division into sections, but it was finally accepted. However, the commonality was by no means completely abolished: the local newspaper wrote about the evening get-together at the 67th meeting in Lübeck in 1895: "One dined I sections and sang together.

    How did Oken react?
    He withdrew somewhat and no longer attended all the meetings. His own activities and commitments took a toll on him in those years. Oken was a committed, pugnacious man who strove for a united Germany, fought for freedom of the press and courageously stood up to his opponents – even if they were sovereigns or named Johann Wolfgang von Goethe. He wrote and published a great deal, campaigned for science education in schools, edited the first interdisciplinary scientific publication “Isis oder Encyclopädische Zeitung” – it appeared from 1819 to 1848 – and finally went to Zurich. There he was appointed the first rector of the university and died in 1851.

    © Deutsches Museum, München, Archiv, CD85577

    View of the auditorium at the celebration of the 150th anniversary of the GDNÄ in Munich in October 1972.

    At that time, the GDNÄ was thirty years old. How was it doing?
    The GDNÄ was doing very well. Its meetings were highlights of scientific and it united the scientific and medical elite of Europe. The lectures, which were printed in proceedings, reflected the development of natural sciences and medicine in the 19th century. Researchers from Italy, England, France, Russia and other countries came to the meetings, even if this was not politically safe for some. Inspired by the GDNÄ's example, similar societies were founded abroad: in 1831 the British Association for the Advancement of Science, two years later the Congrès Scientifiques de France and in 1839 the Italian Riunioni degli Scienziati Italiani. In Germany, numerous scientific and medical societies emerged from the GDNÄ – in physics as well as in chemistry, pharmacy, pathology, gynaecology, surgery and psychiatry. 

    The 20th century was marked by war and reconstruction. How did this affect the GDNÄ?
    During both world wars, meetings were suspended. During the Third Reich, the situation was extremely complex in the three assemblies in 1934 in Hanover, 1936 in Dresden and 1938 in Berlin. In their welcoming speeches, the First Chairmen affirmed the new Nazi era, sometimes with opportunistic rhetoric, sometimes with inner conviction. They dealt with the relationship between German and international research in different emphases, spoke of an orientation towards the national welfare and the benefit for mankind, and at the same time gratefully emphasised the participation of foreign scientists.  The scientific and medical lectures were predominantly free of Nazi ideology, although the lectures on hereditary biology certainly corresponded to the racial ideological discussions of the time. Overarching lectures, such as those by Werner Heisenberg on “Changes in the Foundations of the Exact Sciences in Recent Times” in 1934, by Walter Gerlach on “Theory and Experiment in Exact Science” in 1936 or by Ludwig Aschoff in 1936 on “Pathology and Biology”, were purely scientific and theoretical and explicitly without any connection to the world of politics. The first post-war meeting did not take place again until 1950 in Munich – with a keynote address by the then Federal President Theodor Heuss.

    More than seventy years have passed since then. Is there a defining development in this long period of time that is still noticeable today that you would single out?
    Yes, it has to do with the impetuous optimism about progress that characterised the end of the 19th century and the beginning of the 20th century and which was problematised in the 1970s at the latest. The Heidelberg medical historian Heinrich Schipperges outlined the new attitude in 1972, on the occasion of the 150th anniversary of the GDNÄ, in my opinion very aptly: “At the end of the 20th century, we no longer expect that rational social development is coupled with the progress of scientific discoveries and inventions.” However, he added: “We remain convinced that science is still the most reliable instrument for managing progress.”

    What is the importance of the GDNÄ today? What function can it assume in the spectrum of science organisations?
    The dialogue with the public, which the GDNÄ has always cultivated, is important. In the 19th century, leading naturalists such as the naturalist and natural philosopher Gotthelf Heinrich von Schubert wrote natural science books for school lessons. Today, unfortunately, there is no such thing. In the mid-1990s, an educational commission of the GDNÄ had developed convincing concepts for general science education as, as it put it, “interdisciplinary subject teaching”. However, the implementation in teacher training and everyday school life is still pending. In addition, the GDNÄ as an independent institution is excellently suited to take up central and controversial issues from the natural sciences and medicine for society and culture and to bring them into public discussion. Last but not least, I would like to see it build bridges to the humanities, also to shed light on connections between knowledge of the world and self-knowledge and to address ethical and legal challenges of the present. 

    One question in conclusion: Today, the term “natural researcher” in the GDNÄ name sounds somewhat antiquated. What did people mean by it two hundred years ago?
    If we leave out the natural philosophical dimensions, natural research at that time meant roughly what we understand by natural sciences today. The fact that this term finally prevailed has to do with influences from abroad and the English language. I still consider the term “natural researcher” to be meaningful, attractive and by no means antiquated. In contrast to “natural science” and in agreement with the French “recherche” and English “research”, it emphasises the searching, the questioning, the setting out into the unknown. This is what it is all about, today just as it was when the Society of German Natural Scientists was founded in 1822. 

    Saarbrücken 2018 © Robertus Koppies

    © Institut für Medizingeschichte und Wissenschaftsforschung Lübeck

    The science historian Prof. Dr. Dietrich von Engelhardt.

    About the person
    Dietrich von Engelhardt was born in Göttingen in 1941. He studied philosophy, history and Slavic studies in Tübingen, Munich and Heidelberg, received his doctorate in 1969, worked for several years in criminology and criminal therapy and habilitated in 1976 in the Faculty of Natural Sciences and Medicine at the University of Heidelberg. From 1983 to 2007 he was full professor for the history of medicine and general history of science at the University of Lübeck, and from 2008 to 2011 he was acting director of a comparable Institute at the Technical University of Munich (TUM). Dietrich von Engelhardt took on many other responsibilities, including Prorector of the University of Lübeck (1993 to 1996), President of the Academy for Ethics in Medicine (1998 to 2002), Chairman of the Ethics Committee for Medical Research and the Clinical Ethics Committee of the University of Lübeck (2000 to 2007), and Vice-President of the Regional Committee for Ethics in South Tyrol (2001 to 2010). In 1997 he initiated and organised a symposium in Lübeck on the occasion of the 175th anniversary of the GDNÄ.

    Dietrich von Engelhardt has been honoured several times, for example by being admitted to the German Academy of Sciences Leopoldina in 1995 and to other national and international scientific academies. He received the Georg Maurer Medal of the TUM Faculty of Medicine in 2004 and the prize of the Zurich Margrit Egnér Foundation, also in 2004. In 2016, he was awarded the Alexander von Humboldt Medal for his research on the history of the GDNÄ.

    Dietrich von Engelhardt's scientific focus areas include: Theory of Medicine; Medical Ethics; Medicine in Modern Literature; 16th Century Botany: Natural Philosophy, Natural Science and Medicine in Idealism and Romanticism; History of Psychiatry; Scientific and Medical Journeys in Modern Times; European Scientific Relations; Dealing with Illness by the Sick; Bibliotherapy; Biographies and Pathographies of Natural Scientists, Physicians and Artists.

    Further links:

    Books (Ed. Dietrich von Engelhardt)

    >> Forschung und Fortschritt, Festschrift zum 175-jährigen Jubiläum der Gesellschaft Deutscher Naturforscher und Ärzte, Stuttgart 1997 (anthology with seminal speeches from Lorenz Oken to Hubert Markl; available in antiquarian bookshops)
    >> Zwei Jahrhunderte Wissenschaft und Forschung in Deutschland, Entwicklungen – Perspektiven (Two Centuries of Science and Research in Germany, Developments – Perspectives), Stuttgart 1998 (conference proceedings on the occasion of the 175th anniversary of the GDNÄ; available in antiquarian bookshops)

    © G. C. Wilder / Stadtmuseum Fembo-Haus, Nürnberg

    On the occasion of the 23rd meeting of the „Gentlemen Natural Scientists and Physicians” in 1845, the city of Nuremberg invited to a banquet in the town hall.

    Tina Romeis – Fascinating and beautiful

    „Fascinating and beautiful“

    They provide oxygen and food and create a healthy environment: plants are vital and yet increasingly threatened. Professor Tina Romeis at the Leibniz Institute of Plant Biochemistry (IPB) in Halle is researching how their resistance to drought and other stress factors can be specifically improved.

    Professor Romeis, climate change is affecting plants worldwide. Even in our latitudes, trees, shrubs and many other plants have been affected by the droughts of recent years. Does this concern you in your research?
    Yes, drought stress is a major issue for me and many of my colleagues here at the institute. As basic researchers, we want to understand down to the molecular details what happens in plants during prolonged water shortages. With this knowledge, it should be possible to increase their resistance in a targeted way.

    How are you tackling the problem?
    Our institute specializes in small molecules. We focus on certain metabolites that make a decisive contribution to a plant's resistance to drought. We determine such metabolites in plants that cope differently well with water shortages. Trees such as beech and oak still have a fairly high drought tolerance, while conifers have major problems. We also identify the small molecules in signaling pathways that spread information about environmental conditions within a plant. The plant also uses these pathways to mobilize its defenses, for example in the event of water shortage.

    Das deutsche Tiefsee-Forschungsschiff „Sonne" © Thomas Walter

    © IPB

     In the foyer of the Leibniz Institute of Plant Biochemistry (IPB) in Halle.

    How can we imagine plant defenses?
    When plants are attacked, for example by bacteria or feeding insects, they activate defense mechanisms and substances with which they can defend themselves against future attacks. Calcium-dependent protein kinases are involved in this, and I am particularly interested in them in my research. These are enzymes that are not only important for the immune defense of plants, they also shape plant stress tolerance to drought, cold and nutrient deficiency. Interestingly, there are similar calcium-regulated protein kinases in the human brain that are critical for learning and memory.

    Can plants also remember?
    Yes, you can certainly say that. Of course, plants don't have a brain or nervous system like we humans do. But they do have a kind of molecular memory. My research group is investigating exactly how it works, what information plants store in the short or long term, and what factors regulate the forgetting of information.

    What do you do with findings that could be interesting for application?
    If that's the case, we turn to the Leibniz Institute of Plant Genetics and Crop Plant Research in nearby Gatersleben. The exchange and cooperation between our institutes works excellently and the division of roles is mutually agreed: We at the IPB are responsible for basic biochemical research, while Gatersleben has species-rich seed banks that are ideally suited for new breeding or targeted genetic modification.

    Such developments are very important for feeding a growing world population under climate change. Does this have an impact on your work?
    Admittedly, we do not carry out plant breeding, so we do not provide directly applicable solutions. But the questions we ask in our basic biochemical research are naturally guided by global challenges such as climate change. The fact that these research questions urgently need to be answered is also evident from the fact that science in our field is booming worldwide. In Germany, we are currently still in a very good position. However, I am somewhat skeptical about the future. Many young people don't want to do a doctorate after graduation. Among them, I observe a strong interest in nature conservation, environmental management and ecological education - basic research is not their main concern.

    Was that the reason why you moved from Freie Universität Berlin to the Leibniz Research Institute in Halle three years ago?
    I wanted to concentrate on research, and the conditions at the IPB are ideal for that. The equipment we have here is something you can only dream of at most universities. One example is our mass spectrometer, which we use to determine the masses of atoms and molecules in plants, another is the confocal microscope, which makes tiny plant reactions visible. And with the help of so-called FRET microscopy, we can observe biochemical processes in the plant live.

    © IPB

    With this confocal microscope, the scientists led by Professor Romeis study the behaviour of living plants under different conditions, such as severe drought. The image tiles on the screen show the same leaf of the thale cress Arabidopsis thaliana, which is frequently used for research purposes. Individual sphincter cells (stomata) on the underside of a leaf are shown – they control the gas exchange and water balance in the plant. The microscope demonstrates the biochemical processes that lead to the opening of the cells in favourable conditions and to their closing in dry conditions.

    These sound like good prerequisites for success stories.
    And there are always success stories, even across disciplines. Just a few months ago, a spectacular discovery was published to which research at our institute contributed. It was about the trigger of a mysterious neurodegenerative disease in bald eagles, which was identified after years of joint research with American scientists. Since the 1990s, the disease had killed many birds, reptiles and fish in the southern United States. The cause was a toxin produced by cyanobacteria that thrive on certain aquatic plants in the affected areas. The study was published as a cover story in the journal "Science" and brought large reputation to plant research in Halle. My colleagues at the institute have now just succeeded in the total chemical synthesis of this toxin, which is a toxic metabolite.

    The study was also reported in the German media. Was that due to the attractive topic or is public interest in scientific topics generally high?
    It had a lot to do with the particular subject matter. In general, I'm observing an increasing scientific fatigue and a loss of confidence. The many plagiarism scandals have done a lot of damage to the relationship between science and society. We have a lot of catching up to do.

    What role can the GDNÄ play in this? After all, the exchange with society is one of its major concerns.
    I believe that the GDNÄ can achieve a lot here. It is a neutral body and does not represent any specific professional interests. That is a good basis for a trusting dialog with the public.

    In the GDNÄ, you have recently started representing the subject of biology. What would you like to achieve in this function?
    Plants are extremely important for our lives, for energy supply and the entire ecosystem, and they are becoming increasingly important. In addition, plants are beautiful and fascinating. I would like to raise awareness of that and also communicate it to the next generation. The GDNÄ's programs for students and teachers offer excellent opportunities for this.

    Saarbrücken 2018 © Robertus Koppies

    © IPB

    Prof. Dr. Tina Romeis

    © IPB

    A research facility in green surroundings.

    About the person
    Since 2019, Tina Romeis has headed the "Biochemistry of Plant Interactions" department at the Leibniz Institute of Plant Biochemistry (IPB) in Halle an der Saale. At the same time, the then 54-year-old was appointed professor at Martin Luther University Halle-Wittenberg.  Prior to this, Tina Romeis had headed the Department of Plant Biochemistry at Freie Universität Berlin for 15 years. The call to Berlin was preceded by research activities at the Max Planck Institute for Plant Breeding Research in Cologne, Germany. There she was able to establish herself as an independent group leader thanks to the highly endowed Sofia Kovalevskaja Award of the Alexander von Humboldt Foundation, which she received in 2001. Her habilitation in genetics and molecular phytopathology took place at the Institute of Genetics of the Ludwig-Maximilians-University of Munich. Further milestones in her career were research residencies in Munich and at the John Innes Centre in Norwich, UK, and before that a PhD at the Max Planck Institute for Developmental Biology in Tübingen. In Tübingen, at the Eberhard Karls University, Tina Romeis studied biochemistry, organic chemistry and plant physiology. Born in Würzburg, she grew up in the Steigerwald region of Franconia.

    Professor Romeis' research interests focus in particular on calcium-dependent protein kinases. These enzymes are not only important for the immune defense of plants, they also shape their stress tolerance to drought, cold and nutrient deficiency. The biochemist wants to make her basic research useful in cooperation with research institutions in the region: both for agriculture and forestry as well as for understanding ecological relationships.

    Further links: